For anyone in Lebus looking to source CJC-1295, the foundational reality is that this compound moves through online research channels. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor controls every quality variable. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. The sections below cover what Lebus researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Lebus comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are signalling genuine quality commitment. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. For Lebus researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is standard practice in the community. The powdered lyophilised form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Lebus
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Temperature excursions — even short periods above −20°C — can compromise product integrity without detectable changes to appearance; always verify cold chain was maintained during shipping. The main safety concern arising from sourcing in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the specific protection against this risk. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
